NL301217I2 - tirzepatide en farmaceutisch aanvaardbare zouten daarvan - Google Patents

tirzepatide en farmaceutisch aanvaardbare zouten daarvan

Info

Publication number
NL301217I2
NL301217I2 NL301217C NL301217C NL301217I2 NL 301217 I2 NL301217 I2 NL 301217I2 NL 301217 C NL301217 C NL 301217C NL 301217 C NL301217 C NL 301217C NL 301217 I2 NL301217 I2 NL 301217I2
Authority
NL
Netherlands
Prior art keywords
tirzepatide
pharmaceutically acceptable
acceptable salts
salts
pharmaceutically
Prior art date
Application number
NL301217C
Other languages
English (en)
Other versions
NL301217I1 (nl
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55315708&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301217(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NL301217I1 publication Critical patent/NL301217I1/nl
Publication of NL301217I2 publication Critical patent/NL301217I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
NL301217C 2015-01-09 2023-02-07 tirzepatide en farmaceutisch aanvaardbare zouten daarvan NL301217I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562101488P 2015-01-09 2015-01-09
PCT/US2016/012124 WO2016111971A1 (en) 2015-01-09 2016-01-05 Gip and glp-1 co-agonist compounds

Publications (2)

Publication Number Publication Date
NL301217I1 NL301217I1 (nl) 2023-02-15
NL301217I2 true NL301217I2 (nl) 2023-04-04

Family

ID=55315708

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301217C NL301217I2 (nl) 2015-01-09 2023-02-07 tirzepatide en farmaceutisch aanvaardbare zouten daarvan

Country Status (45)

Country Link
US (1) US9474780B2 (nl)
EP (2) EP3597662A1 (nl)
JP (3) JP6219534B2 (nl)
KR (4) KR101957620B1 (nl)
CN (2) CN112608377B (nl)
AR (1) AR103242A1 (nl)
AU (1) AU2016205435B2 (nl)
CA (1) CA2973352C (nl)
CL (1) CL2017001760A1 (nl)
CO (1) CO2017006737A2 (nl)
CR (1) CR20170310A (nl)
CY (1) CY1122028T1 (nl)
DK (1) DK3242887T3 (nl)
DO (1) DOP2017000153A (nl)
EA (3) EA031591B1 (nl)
EC (1) ECSP17043648A (nl)
ES (1) ES2747928T3 (nl)
FI (1) FIC20230005I1 (nl)
FR (1) FR23C1006I2 (nl)
HR (1) HRP20191614T1 (nl)
HU (2) HUE045860T2 (nl)
IL (3) IL252499B (nl)
JO (2) JOP20200119A1 (nl)
LT (2) LT3242887T (nl)
MA (2) MA41315B1 (nl)
MD (1) MD3242887T2 (nl)
ME (1) ME03494B (nl)
MX (2) MX2017008927A (nl)
MY (1) MY193616A (nl)
NL (1) NL301217I2 (nl)
NO (1) NO2023005I1 (nl)
NZ (1) NZ732000A (nl)
PE (1) PE20170954A1 (nl)
PH (1) PH12017501252A1 (nl)
PL (1) PL3242887T3 (nl)
PT (1) PT3242887T (nl)
RS (1) RS59146B1 (nl)
SG (1) SG11201705603YA (nl)
SI (1) SI3242887T1 (nl)
SV (1) SV2017005453A (nl)
TN (1) TN2017000198A1 (nl)
TW (1) TWI582109B (nl)
UA (1) UA118239C2 (nl)
WO (1) WO2016111971A1 (nl)
ZA (1) ZA201703930B (nl)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2933701C (en) 2013-12-18 2022-05-31 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2018104263A1 (en) 2016-12-06 2018-06-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
US11590237B2 (en) 2017-05-18 2023-02-28 Merck Sharp & Dohme Llc Pharmaceutical formulation comprising incretin-insulin conjugates
TWI744579B (zh) * 2017-12-21 2021-11-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI767095B (zh) * 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
WO2019140030A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
CN112074531A (zh) * 2018-05-04 2020-12-11 诺和诺德股份有限公司 Gip衍生物及其用途
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
WO2020023382A1 (en) 2018-07-23 2020-01-30 Eli Lilly And Company Methods of using a gip/glp1 co-agonist for therapy
EP3827015A1 (en) * 2018-07-23 2021-06-02 Eli Lilly and Company Gip/glp1 co-agonist compounds
IL280159B1 (en) * 2018-07-23 2024-01-01 Lilly Co Eli Methods of using a GIP/GLP1 co-agonist for diabetes
JP6564539B1 (ja) 2018-09-14 2019-08-21 長瀬産業株式会社 スルホン酸化合物によるペプチド精製方法
WO2020067575A1 (en) 2018-09-24 2020-04-02 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
TWI799680B (zh) * 2019-01-29 2023-04-21 美商美國禮來大藥廠 製備gip/glp1雙重促效劑之方法
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
AR119471A1 (es) 2019-08-01 2021-12-22 Lilly Co Eli Compuestos agonistas de gipr
EP4017866A1 (en) 2019-08-19 2022-06-29 Eli Lilly and Company Methods of making incretin analogs
WO2021066600A1 (ko) 2019-10-04 2021-04-08 한미약품 주식회사 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
TWI795698B (zh) * 2019-12-18 2023-03-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI770781B (zh) * 2020-01-23 2022-07-11 美商美國禮來大藥廠 Gip/glp1共促效劑化合物
TW202140058A (zh) * 2020-01-30 2021-11-01 美商美國禮來大藥廠 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途
CN111253475B (zh) * 2020-02-18 2021-03-09 江苏诺泰澳赛诺生物制药股份有限公司 Glp-1激动多肽化合物及其盐与合成方法及用途
KR20220145888A (ko) 2020-03-06 2022-10-31 사노피 선택적 gip 수용체 작용제로서의 펩티드
CN113493503B (zh) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 一种肠促胰岛素类似物及其制备方法和用途
TW202216746A (zh) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
EP4185607A1 (en) * 2020-07-22 2023-05-31 Novo Nordisk A/S Co-agonists at glp-1 and gip receptors suitable for oral delivery
JP2023534130A (ja) 2020-07-22 2023-08-08 ノヴォ ノルディスク アー／エス Ｇｌｐ－１受容体およびｇｉｐ受容体共作動薬
EP4222176A4 (en) * 2020-09-30 2024-02-28 Beijing Ql Biopharmaceutical Co Ltd POLYPEPTIDE CONJUGATES AND METHODS OF USE
US20240020543A1 (en) 2020-10-17 2024-01-18 Sun Pharmaceutical Industries Limited Glp-1/gip dual agonists
AU2021391241B2 (en) * 2020-12-02 2024-05-09 Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd Lactam-modified polypeptide compounds
WO2022159395A1 (en) * 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
CA3208873A1 (en) * 2021-02-17 2022-08-25 Mathijs Christiaan Michael BUNCK Gip/glp1 dual agonist therapeutic methods
JP2024510090A (ja) 2021-02-17 2024-03-06 イーライ リリー アンド カンパニー チルゼパチド治療方法
AU2022245736A1 (en) * 2021-03-25 2023-10-12 Brightgene Bio-Medical Technology Co., Ltd. Gip and glp-1 dual receptor agonist, pharmaceutical composition, and use
EP4333814A1 (en) 2021-05-07 2024-03-13 Eli Lilly and Company Erodible tablet
WO2022247950A1 (zh) * 2021-05-28 2022-12-01 广东众生睿创生物科技有限公司 多肽的制备及其应用
CA3222051A1 (en) * 2021-06-01 2022-12-08 Nanjing Zhihe Medicine Technology Co., Ltd. Polypeptide derivative having effect of dual targeted activation of glp-1r and gipr, preparation method therefor, and use thereof
TW202302624A (zh) * 2021-06-18 2023-01-16 大陸商廣東眾生睿創生物科技有限公司 含內醯胺橋的多肽化合物
WO2023031455A1 (en) 2021-09-06 2023-03-09 Sanofi Sa New peptides as potent and selective gip receptor agonists
JP2024508096A (ja) * 2021-09-15 2024-02-22 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023084118A1 (en) 2021-11-15 2023-05-19 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023089594A1 (en) 2021-11-22 2023-05-25 Sun Pharmaceutical Industries Limited Process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
WO2023193727A1 (zh) * 2022-04-07 2023-10-12 广东众生睿创生物科技有限公司 多肽在制备治疗和/或预防糖尿病及肥胖症及其相关疾病药物中的制药用途
EP4299052A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and a permeation enhancer
WO2024006662A1 (en) 2022-06-30 2024-01-04 Eli Lilly And Company Tirzepatide compositions and use
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
CN117402219A (zh) * 2022-07-13 2024-01-16 杭州中美华东制药有限公司 Glp-1/gip双激动剂及其制备方法和用途
WO2024020388A1 (en) * 2022-07-20 2024-01-25 Viking Therapeutics, Inc. Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders
WO2024050289A1 (en) 2022-08-29 2024-03-07 Eli Lilly And Company Compositions for oral delivery
WO2024059674A1 (en) 2022-09-15 2024-03-21 Eli Lilly And Company Gip and glp-1 dual agonist compounds
WO2024061310A1 (zh) * 2022-09-23 2024-03-28 博瑞生物医药（苏州）股份有限公司 一种glp-1和gip双受体激动剂药物组合物及其用途
WO2024077149A2 (en) 2022-10-05 2024-04-11 Eli Lilly And Company Peptides for incretin synthesis
CN116832141B (zh) * 2023-06-06 2024-02-09 诺博泰科(成都)生物科技有限公司 一种用于治疗糖尿病的glp-1、gip和gcg受体三激动多肽化合物
CN116693652B (zh) * 2023-08-02 2024-01-05 北京惠之衡生物科技有限公司 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US20080171695A1 (en) * 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
JP2011530507A (ja) * 2008-08-07 2011-12-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ グルコース依存性インスリン分泌刺激ポリペプチドアナログ
CN102149411A (zh) 2008-09-12 2011-08-10 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
CN101367873B (zh) * 2008-10-08 2011-05-04 南开大学 一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用
KR20110110174A (ko) 2008-12-19 2011-10-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드 기반 글루카곤 슈퍼패밀리 펩티드 프로드럭
GB0917072D0 (en) * 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
RU2012136450A (ru) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
AR080592A1 (es) * 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
KR101091041B1 (ko) * 2010-07-29 2011-12-09 고려대학교 산학협력단 새로운 재조합 글루코스 의존성 인슐린분비 펩타이드(ｒｃＧＩＰ) 작용제 및 그 용도
MA34885B1 (fr) 2010-12-22 2014-02-01 Indiana Unversity Res And Technology Corp Analogues du glucagon presentant una ctivite de recepteur de gip
AR084558A1 (es) * 2010-12-22 2013-05-22 Marcadia Biotech Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1)
EP2694095B1 (en) 2011-04-05 2018-03-07 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
WO2012167744A1 (en) 2011-06-10 2012-12-13 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
WO2012171994A1 (en) 2011-06-15 2012-12-20 Novo Nordisk A/S Multi substituted insulins
TWI596110B (zh) 2011-09-23 2017-08-21 諾佛 儂迪克股份有限公司 新穎升糖素類似物
EP2793931A2 (en) * 2011-12-23 2014-10-29 Zealand Pharma A/S Glucagon analogues
IN2014MN02304A (nl) * 2012-05-03 2015-08-07 Zealand Pharma As
RU2015101697A (ru) * 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, обладающие активностью рецептора gip
EP2908845A1 (en) 2012-10-17 2015-08-26 Novo Nordisk Health Care AG Fatty acid acylated amino acids for growth hormone delivery
ES2688367T3 (es) 2012-12-21 2018-11-02 Sanofi Derivados de exendina-4 como agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón
TWI638831B (zh) 2013-05-28 2018-10-21 日商武田藥品工業股份有限公司 胜肽化合物

Also Published As

Publication number Publication date
PL3242887T3 (pl) 2020-02-28
CA2973352C (en) 2019-03-26
IL281545A (en) 2021-05-31
CL2017001760A1 (es) 2018-03-16
JP2019203000A (ja) 2019-11-28
CR20170310A (es) 2017-08-17
EA035055B1 (ru) 2020-04-22
KR20230023822A (ko) 2023-02-17
ES2747928T3 (es) 2020-03-12
TWI582109B (zh) 2017-05-11
PE20170954A1 (es) 2017-07-13
NZ748274A (en) 2022-03-25
FR23C1006I2 (fr) 2024-01-05
US20160199438A1 (en) 2016-07-14
KR20210145311A (ko) 2021-12-01
EA202090392A3 (ru) 2020-08-31
SV2017005453A (es) 2018-08-27
LT3242887T (lt) 2019-11-11
MA41315A (fr) 2017-11-15
JOP20200119A1 (ar) 2017-06-16
CN112608377A (zh) 2021-04-06
HUE045860T2 (hu) 2020-01-28
JP2018052933A (ja) 2018-04-05
EP3597662A1 (en) 2020-01-22
JP2017507124A (ja) 2017-03-16
CA2973352A1 (en) 2016-07-14
AU2016205435B2 (en) 2018-03-29
EP3242887B1 (en) 2019-08-14
NL301217I1 (nl) 2023-02-15
FIC20230005I1 (fi) 2023-02-02
IL276492B (en) 2021-04-29
SI3242887T1 (sl) 2019-10-30
KR102330764B1 (ko) 2021-11-25
US9474780B2 (en) 2016-10-25
IL276492A (en) 2020-09-30
LTPA2023504I1 (nl) 2023-02-27
IL252499A0 (en) 2017-07-31
JO3575B1 (ar) 2020-07-05
TW201636362A (zh) 2016-10-16
KR20190026967A (ko) 2019-03-13
RS59146B1 (sr) 2019-09-30
MD3242887T2 (ro) 2019-11-30
SG11201705603YA (en) 2017-08-30
CN107207576B (zh) 2020-11-24
UA118239C2 (uk) 2018-12-10
EA202090392A2 (ru) 2020-05-31
JP6219534B2 (ja) 2017-10-25
HRP20191614T1 (hr) 2019-12-13
MA41315B1 (fr) 2019-11-29
PT3242887T (pt) 2019-10-29
WO2016111971A1 (en) 2016-07-14
NO2023005I1 (no) 2023-02-02
MX2017008927A (es) 2017-10-11
FR23C1006I1 (fr) 2023-03-24
BR112017010596A2 (pt) 2018-03-06
DOP2017000153A (es) 2017-07-15
ECSP17043648A (es) 2017-11-30
MX2021005835A (es) 2021-07-15
MA50422A (fr) 2020-08-26
ZA201703930B (en) 2019-06-26
CY1122028T1 (el) 2020-10-14
EA201892057A1 (ru) 2019-02-28
DK3242887T3 (da) 2019-09-02
TN2017000198A1 (en) 2018-10-19
HUS2300006I1 (hu) 2023-02-28
MY193616A (en) 2022-10-20
EP3242887A1 (en) 2017-11-15
NZ732000A (en) 2018-11-30
CN112608377B (zh) 2024-02-13
AR103242A1 (es) 2017-04-26
IL252499B (en) 2020-08-31
CO2017006737A2 (es) 2017-09-29
JP6545766B2 (ja) 2019-07-17
KR20170092661A (ko) 2017-08-11
ME03494B (me) 2020-01-20
CN107207576A (zh) 2017-09-26
EA201791281A1 (ru) 2017-11-30
AU2016205435A1 (en) 2017-06-08
JP6754867B2 (ja) 2020-09-16
EA031591B1 (ru) 2019-01-31
KR101957620B1 (ko) 2019-03-13
PH12017501252A1 (en) 2017-10-30

Similar Documents

Publication Publication Date Title
NL301217I2 (nl) tirzepatide en farmaceutisch aanvaardbare zouten daarvan
NO2022046I1 (no) Berotralstat and pharmaceutically acceptable salts thereof
NL301094I2 (nl) Avapritinib en farmaceutisch aanvaardbare zouten daarvan
NO2021035I1 (no) Risdiplam or a pharmaceutically acceptable salt thereof
DK3393510T3 (da) Zikavirusvaccine
BR112018009951A2 (pt) fármaco oftálmico
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
DK3310414T3 (da) Lægemiddeladministrationsanordning
FIC20240013I1 (fi) Lebrikitsumabi
BR112017027227A2 (pt) Agente anti-câncer
DK3199161T3 (da) Farmaceutisk præparat
DK3560925T3 (da) Hidtil ukendt forbindelse og farmaceutisk acceptabelt salt deraf
DK3463345T3 (da) Farmaceutiske kombinationer
DK3408265T3 (da) Terapeutiske forbindelser
DK3386956T3 (da) Fumagillolderivater og polymorfer deraf
DK3191148T3 (da) Lægemiddelindretninger med reduceret thrombogenicitet
DK3280447T3 (da) Farmaceutiske formuleringer
DK3380465T3 (da) Diaminopyridinderivativer
DK3288967T3 (da) Farmaceutisk forbindelse
ES1147609Y (es) Batea
DE112017003625A5 (de) Difluorstilben-Derivate
DK3288966T3 (da) Farmaceutisk forbindelse
UA33364S (uk) Стілець
UA32568S (uk) Крісло-гойдалка
ES1148508Y (es) Taburete perfeccionado